Innovus Pharmaceuticals Inc. (fka INNV)

[Honeycomb777]

HC’s RESEARCH RESULTS (completed on Sunday 2/12/17, using info. from 2/10 market close):

If I may, I was absolutely BLOWN AWAY with my findings. Below you will see 5 stocks (3 OTCQB and 2 NASDAQ) that have a similar number of outstanding shares as INNV and that all had/have Revenue. I encourage you to make use of CNBC.com for further evaluation, but here are highlights. Again, the purpose of this is to gauge if YOU feel that INNV is undervalued, overvalued, or “right on” compared to these listings and their data. If inclined, please do further DD as this is a great starting point. Enjoy

http://data.cnbc.com/quotes/innv
122M o/s-Trades on OTCQB RSI 33.3 Three-star Morningstar Rating

NWBO (OTCQB) trading at .46 pps with 156.3M o/s RSI 56.8
- $2.59 pps was its 52 week high
- $1.4M in Annual Revenue
- Huge Net LOSS of $32M for Q3 2016 but still carries a 3-star Morningstar rating
- Negative Total Stockholders Equity / [450M authorized shares]

AFTM (OTCQB) trading at .325 pps with 104.3M o/s RSI 56.7
- Only $153k in Annual Revenue but stock trades Twice as high as INNV
- Net Loss / Total Liabilities are also 3x greater than Total Assets

IDRA (NASDAQ) trading at $1.60 pps with 147.7M o/s RSI 59.0
- $1.1M in Annual Revenue
- Negative EPS / Escalating Royalties hitting but can large PR’d “milestone” amounts be trusted ?

FOLD (NASDAQ) trading at $6.20 pps with 142.3M o/s RSI 63.8
- $9.83 pps was its 52 week high folks (Nine dollars and 83 cents - WOW)
- $2.13M in Q3 2016 Revenue
- Negative EPS

* Now, you may need to catch your breath with these 4 examples - but try this last one on for size:

RGBP (OTCQB) trading at .057 pps with 145.4M o/s RSI 27.8 [500M authorized shares] < $225k of cash
- ~$100k in Revs (that’s one hundred thou) INNV will likely have 54x this in Revs with same o/s
- INNV trades < 3x higher than this ticker and is on the same exchange. (JAW DROPPING)
- Negative Operating Income (getting worse) and fairly large increase in o/s from 9/2015 to now

I see (likely case) that INNV o/s count grows from 122M to 147.7M soon – once Novaleres’ shares are registered and then, perhaps, an additional 11-12M shares coming from the recent s-1 filing. So, ~159M outstanding is my target when it all shakes out months down the road. I feel this is a fair estimate (+,- 1M shares). I strongly believe that 2016 revenue guidance will be beat and come in around $5.5M. I will be interested to see if guidance is revised for all of 2017?

In conclusion, well, I will simply let you draw your own - based on some semblance of reality. That was the entire point of doing this for all of you. Some posters may think it’s more about perception and excuses. In my view, when you have certain stocks trading at much higher levels with larger losses (and trending for even bigger ones), more outstanding shares, declining margins, and less revenue than INNV has it is difficult not to conclude that we have been treated harshly by Mr. Market. So, please analyze the above 5 tickers yourself and feel free to share this PUBLICLY AVAILABLE data/information. I would encourage you to take a closer look at the Income Statements, Balance Sheets, and Cash Flow information vs. that of Dr. Damaj’s INNV.

*Full Disclosure: HC is a long

TWO BONUS TICKERS TO RESEARCH & REVIEW FOLKS – JUST BECAUSE:

MCIG (OTCQB) trading around 39 cents with 340M o/s and $1.3M in Revenue

IMMG (OTCQB) trading around 60 cents with 152M o/s

As always, buy some INNV products & tell 2 friends. Please Support the bottom line-GLTY! Tweet Tweet